Former Warwick Chemistry researcher Dr Suzanne Dilly will, it was announced today, lead a new company ValiSeek Limited, a risk-sharing joint venture company between Tangent Reprofiling Limited, a member of the SEEK group, and ValiRx Plc, the life science company with a focus on cancer diagnostics and therapeutics for personalised medicine. ValiSeek has acquired a worldwide exclusive licence from Tangent to progress the drug VAL401, discovery of which was aided by Warwick Chemistry’s Magic Tag® technology, through its remaining preclinical development and towards Phase II trials for the treatment of lung cancer and other oncology indications.

http://www.valirx.com/rns-announcements/view/valirx-plc-valiseek-joint-venture